Lilly Will Not Settle Zyprexa Overpricing Suit; Judge Finds Evidence Of Fraud
Executive Summary
Lilly intends to fight rather than settle a suit by third party payers alleging the company overpriced its antipsychotic drugZyprexa (olanzapine)
You may also be interested in...
Third-Party Payers Have No Class: Zyprexa Ruling Cites Non-Uniform Pricing In Tossing Out Group Challenge
Third-party payers had hoped to obtain billions in damages in a suit claiming Eli Lilly & Co. misrepresented the side effects and safety of its antipsychotic Zyprexa (olanzapine). But an appeals court reversed their class certification and also found that they could not proceed with their main theory of damages as individual plaintiffs.
Third-Party Payers Have No Class: Zyprexa Ruling Cites Non-Uniform Pricing In Tossing Out Group Challenge
Third-party payers had hoped to obtain billions in damages in a suit claiming Eli Lilly & Co. misrepresented the side effects and safety of its antipsychotic Zyprexa (olanzapine). But an appeals court reversed their class certification and also found that they could not proceed with their main theory of damages as individual plaintiffs.
Lilly Wins Victory In Mississippi Zyprexa Case; Judge Says "Aggregate Proof" Of Liability Is Insufficient For Determining Fines
A federal judge has tossed out most of Mississippi's lawsuit against Lilly over Zyprexa marketing and rebuked the state for seeking excessive penalties